Circulating CLA+ T cell subsets inversely correlate with disease severity and extension in acute psoriasis but not in chronic plaque psoriasis

European Journal of Dermatology

Volumn 18, Issue 6, 2008, Pages 647-650

  Ferran, Marta ^a   Giménez Arnau, Ana M ^a   Bellosillo, Beatriz ^a   Pujol, Ramon M ^a   Santamaria Babi, Luis F ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

BSA; CLA; Cutaneous lymphocyte associated antigen; PASI; Psoriasis

Indexed keywords

CD3 ANTIGEN; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY SURFACE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FLOW CYTOMETRY; HUMAN; PATHOPHYSIOLOGY; PSORIASIS; PSORIASIS SEVERITY INDEX; T LYMPHOCYTE SUBPOPULATION;

ACUTE DISEASE; ADULT; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; FLOW CYTOMETRY; HUMANS; MEMBRANE GLYCOPROTEINS; PSORIASIS; SKIN; T-LYMPHOCYTE SUBSETS;

EID: 57749190998     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2008.0513     Document Type: Article

References (28)

1. Schön MP, Zollner TM, Boehncke WH. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol 2003; 121: 951-62.
2. Santamaria-Babi LF. CLA (+) T cells in cutaneous diseases. Eur J Dermatol 2004; 14: 13-8.
3. Santamaria Babi LF, Picker LJ, Perez Soler MT, Drzimalla K, Flohr P, Blaser K, Hauser C. Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. J Exp Med 1995; 181: 1935-40.
4. Pont-Giralt M, Giménez-Arnau AM Pujol RM, Santamaria-Babi LF. Circulating CLA(+) T cells from acute and chronic psoriasis patients manifest a different activation state and correlation with disease severity and extension. J Invest Dermatol 2006; 126: 227-8.
5. Santamaria-Babi LF. Skin-homing T cells in cutaneous allergic inflammation. Chem Immunol Allergy 2006; 91: 87-97.
6. Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in humans. Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990; 136: 1053-68.
7. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899-912.
8. Sabat R, Philipp S, Höflich C, Kreutzer S, Wallace E, Asadullah K, Volk HD, Sterry W, Wolk K. Immunopathogenesis of psoriasis. Exp Dermatol 2007; 16: 779-98.
9. van de Kerkhof PC. The evolution of the psoriatic lesion. Br J Dermatol 2007; 157: 4-15.
10. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
11. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-7.
12. Sigmundsdottir H, Gudjonsson JE, Jonsdottir I, Ludviksson BR, Valdimarsson H. The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol 2001; 126: 365-9.
13. Sigmundsdottir H, Johnston A, Gudjonsson JE, Bjarnason B, Valdimarsson H. Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyteassociated antigen and the numbers of mononuclear leucocytes in psoriatic skin. Exp Dermatol 2004; 13: 426-33.
14. Jensen CS, Lisby S, Larsen JK, Veien NK, Menne T. Characterization of lymphocyte subpopulations and cytokine profiles in peripheral blood a nickel-sensitive individuals with systemic contact dermatitis after oral nickel exposure. Contact Dermatitis 2004; 50: 31-8.
15. Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, McCormick TS, Cooper KD. Dysfunctional blood and target tissue CD4+CD25high retatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005; 174: 164-73.
16. Cavani A, Nasorri F, Ottaviani C, Sebastiani S, De Pita O, Girolomoni G. Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol 2003; 171: 5760-8.
17. Diluvio L, Vollmer S, Besgen P, Ellwart JW, Chimenti S, Prinz JC. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 2006; 176: 7104-11.
18. Baker BS, Powles A, Fry L. Peptidoglycan: a major aetiological factor for psoriasis? Trends Immunol 2006; 27: 545-51.
19. Lecewicz-Toruń B, Pietrzak A, Roliński J, Brzozowski W. The peripheral blood lymphocyte pattern in psoriasis preceded by an infection. Med Sci Monit 2001; 7: 889-93.
20. Parent D, Bernard BA, Desbas C, et al. Spreading of psoriatic plaques: alteration of epidermal differentiation precedes capillary leakiness and anomalies in vascular morphology. J Invest Dermatol 1990; 95: 333-40.
21. Ragaz A, Ackerman AB. Evolution, maturation, and regression of lesions of psoriasis. New observations and correlation a clinical and histologic findings. Am J Dermatopathol 1979; 1: 199-214.
22. Davison SC, Ballsdon A, Allen MH, et al. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp Dermatol 2001; 10: 280-5.
23. +) T cells appear early in the marginal zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 2004; 150: 852-9.
24. Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007; 25: 574-80.
25. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-51.
26. Santamaria Babi LF, Moser R, Perez Soler MT, Picker LJ, Blaser K, Hauser C. Migration of skin-homing T cells across cytokine-activated human endothelial cell layers involves interaction of the cutaneous lymphocyte-associated antigen (CLA), the very late antigen-4 (VLA-4), and the lymphocyte function-associated antigen-1 (LFA-1). J Immunol 1995; 154: 1543-50.
27. Vugmeyster Y, Kikuchi T, Lowes MA, Chamian F, Kagen M, Gilleaudeau P, Lee E, Howell K, Bodary S, Dummer W, Krueger JG. efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 2004; 113: 38-46.
28. Kragballe K. Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark. Br J Dermatol 2007; 156(Suppl 2): 7-11.